semaglutide and iih Beyond weight loss: a case study narrative review of the potential role of glucagon-like peptide-1 receptor agonists for the treatment of idiopathic intracranial hypertension - Paulo NeuroOp Guru: Stopping GLP-1 therapy
Description
The rationale is straightforward: each dose increase changes the metabolic and inflammatory environment
Patients in the semaglutide group also lost a mean 9.4% of their body weight at 2 years
As this evidence base rapidly expands, a contemporary synthesis is required to inform clinical decision-making
00298-7/asset/03095195-a8ab-411e-a074-d3b1f648192a/main.assets/gr3_lrg.jpg)
What Would You Like Our Help With Today
They strengthen the gut barrier, reducing the "leaky gut" that allows inflammatory compounds to enter your bloodstream and impair metabolic function
(2014c)
